IP Library › Patent Application 17476753
Patent Application
App. No. 17/476,753

PLATELET-DERIVED GROWTH FACTOR COMPOSITIONS AND METHODS OF USE THEREOF

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
17/476,753
Abstract

A method for promoting growth of bone, periodontium, ligament, or cartilage in a mammal by applying to the bone, periodontium, ligament, or cartilage a composition comprising platelet-derived growth factor at a concentration in the range of about 0.1 mg/mL to about 1.0 mg/mL in a pharmaceutically acceptable liquid carrier and a pharmaceutically-acceptable solid carrier.

Claims (25)

1 - 78 . (canceled)

79 . An implant material comprising a porous calcium phosphate having incorporated therein a solution comprising platelet derived growth factor (PDGF) having a concentration ranging from about 0.1 mg/mL to about 1.0 mg/mL in a buffer, wherein the calcium phosphate comprises interconnected pores, a porosity greater than 40%, and particles having a size ranging from about 100 microns to about 5000 microns,

wherein the calcium phosphate is chosen from one or more of tricalcium phosphate, hydroxyapatite, amorphous calcium phosphate, calcium metaphosphate, dicalcium phosphate dihydrate, heptacalcium phosphate, calcium pyrophosphate dihydrate, calcium pyrophosphate, and octacalcium phosphate, and

wherein the implant material does not comprise demineralized freeze-dried bone allograft.

80 . The implant material of claim 79 , wherein the PDGF comprises recombinant PDGF.

81 . The implant material of claim 79 , wherein the PDGF comprises recombinant human PDGF-BB.

82 . The implant material of claim 79 , wherein the solution comprises PDGF at a concentration of about 0.3 mg/mL.

83 . The implant material of claim 79 , wherein the solution comprises PDGF having a concentration ranging from about 0.25 mg/mL to about 0.5 mg/mL.

84 . The implant material of claim 79 , wherein the solution comprises PDGF having a concentration ranging from about 0.2 mg/mL to about 0.75 mg/mL.

85 . The implant material of claim 79 , wherein the calcium phosphate comprises particles having a size ranging from about 100 microns to about 3000 microns.

86 . The implant material of claim 79 , wherein the calcium phosphate comprises particles having a size ranging from about 250 microns to about 1000 microns.

87 . The implant material of claim 79 , wherein the hydroxyapatite comprises carbonated hydroxyapatite.

88 . The implant material of claim 79 , wherein the calcium phosphate comprises poorly crystalline hydroxyapatite.

89 . The implant material of claim 79 , wherein the calcium phosphate is capable of absorbing an amount of the solution comprising PDGF that is equal to at least about 200% of the calcium phosphate's own weight.

90 . An implant material comprising collagen and a porous calcium phosphate having incorporated therein a solution comprising platelet derived growth factor (PDGF) having a concentration ranging from about 0.1 mg/mL to about 1.0 mg/mL in a buffer, wherein the calcium phosphate comprises interconnected pores, a porosity greater than 40%, and particles having a size ranging from about 100 microns to about 3000 microns,

wherein the calcium phosphate is chosen from one or more of tricalcium phosphate, hydroxyapatite, amorphous calcium phosphate, calcium metaphosphate, dicalcium phosphate dihydrate, heptacalcium phosphate, calcium pyrophosphate dihydrate, calcium pyrophosphate, and octacalcium phosphate, and

wherein the implant material does not comprise demineralized freeze-dried bone allograft.

91 . The implant material of claim 90 , wherein the PDGF comprises recombinant PDGF.

92 . The implant material of claim 90 , wherein the PDGF comprises recombinant human PDGF-BB.

93 . The implant material of claim 90 , wherein the calcium phosphate comprises particles having a size ranging from about 250 microns to about 1000 microns.

94 . The implant material of claim 90 , wherein the solution comprises PDGF having a concentration ranging from about 0.25 mg/mL to about 0.5 mg/mL.

95 . The implant material of claim 90 , wherein the solution comprises PDGF having a concentration ranging from about 0.2 mg/mL to about 0.75 mg/mL.

96 . The implant material of claim 90 , wherein the solution comprises PDGF at a concentration of about 0.3 mg/mL.

97 . The implant material of claim 90 , wherein the hydroxyapatite comprises carbonated hydroxyapatite.

98 . The implant material of claim 90 , wherein the calcium phosphate comprises poorly crystalline hydroxyapatite.